Creative Planning
ARQT icon

Creative Planning’s Arcutis Biotherapeutics ARQT Stock Holding History

Creative Planning’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$880K Buy
33,565
+3,914
+13% +$91.2K ﹤0.01% 2749
2026
Q1 		$699K Buy
29,651
+2,485
+9% +$63.4K ﹤0.01% 2762
2025
Q4 		$789K Buy
27,166
+2,867
+12% +$73.4K ﹤0.01% 2475
2025
Q3 		$458K Buy
24,299
+4,724
+24% +$74.5K ﹤0.01% 2800
2025
Q2 		$274K Buy
19,575
+1,477
+8% +$20.7K ﹤0.01% 2972
2025
Q1 		$283K Sell
18,098
-2,563
-12% -$36.1K ﹤0.01% 2809
2024
Q4 		$288K Buy
20,661
+6,985
+51% +$76.5K ﹤0.01% 2701
2024
Q3 		$127K Buy
+13,676
New +$135K ﹤0.01% 2968

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Creative Planning's ARQT Position: Q2 2026 in Review

Creative Planning increased its Arcutis Biotherapeutics (ARQT) stake by 13% in Q2 2026, buying an estimated $91.2K and bringing the position to 33,565 shares worth $880K. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

Creative Planning first reported a position in ARQT in Q3 2024 and has held it in 8 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Creative Planning held 33,565 shares of Arcutis Biotherapeutics worth $880K as of Q2 2026.
  • Creative Planning bought 3,914 Arcutis Biotherapeutics shares in Q2 2026, an estimated $91.2K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2749 holding.
  • Creative Planning first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.